The API-CAT trial (Apixaban Cancer-Associated Thrombosis) demonstrated that, in patients with active cancer who had completed ...
But do these drugs really herald the end of warfarin, and how do doctors decide which of the three new agents to use? Two experts have quite different views of the situation. Dr Alexander Turpie ...
Apixaban is a generic oral tablet that’s prescribed for certain types of blood clots. It’s available as the brand-name drug Eliquis. The cost of apixaban, with and without insurance, can depend on ...
Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, ...
When older adults with atrial fibrillation (AF) are starting on a direct oral anticoagulant (DOAC) for stroke prevention, they may be better off with apixaban than rivaroxaban. In a study of claims ...
A large, population-based study of patients with atrial fibrillation (AF) and valvular heart disease (VHD) found that use of apixaban was associated with a lower rate of ischemic stroke or systemic ...
Purpose The pharmacology, pharmacokinetics, efficacy, and safety of apixaban are reviewed. Summary Apixaban is an oral, direct, selective factor Xa inhibitor with a rapid onset of action. It has a ...
PRINCETON, N.J. & NEW YORK--(BUSINESS WIRE)-- Bristol-Myers Squibb Company (NYSE: BMY) and Pfizer Inc. (NYSE: PFE) today announced that the ADVANCE-3 study results, published in The New England ...
Blood thinner apixaban found to prevent strokes in patients with device-detected atrial fibrillation
The widely available blood thinner apixaban substantially reduced stroke in at-risk patients with a type of atrial fibrillation only detectable by a pacemaker or other implanted cardiac electronic ...
In older patients with atrial fibrillation (AF), apixaban seems to improve outcomes relative to warfarin regardless of frailty status, whereas other direct oral anticoagulants (DOACs) appear ...
Prophylaxis with apixaban (Eliquis) failed to reduce the rate of venous thromboembolism (VTE) in children with newly diagnosed acute lymphoblastic leukemia or lymphoma, according to results from the ...
The Appraisal Committee reviewed the data available on the clinical and cost effectiveness of apixaban, having considered evidence on the nature of venous thromboembolism and the value placed on the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results